% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • glises581g glises581g Jul 3, 2013 7:35 AM Flag

    Statistically significant side effects

    I've seen this before,The additional data secondary endpoints were omitted from the investor presentation but a peek into the data shows that
    with 125 patients
    Arikace, had 35% more adverse efeects overall
    7.4% of patients(twice as many as TOBI) had severe events
    This issue will come up again

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Which pharma is paying you and the rest of your boiler room gang? Makes no difference. They will have to get on a long line with lots of cash to acquire Insmed some day, if ever. Suggestion: talk to an attorney to find out if what you are doing is legal. Insmed has attorneys who can quickly come after your gang. Have a nice day.

      Sentiment: Buy

    • Wow - another delusional poster under the impression his opinion is of value when we already have the opinion of the Canaccord analyst -

      "We see Arikace as eminently approvable with good safety. While there are optical imbalances in Arikace's severe adverse events, INSM indicated there is no kidney or ototox signal, our main concern."

      Perhaps you should take a closer look at the data already released - and then take a look at the problematical efficacy and safety data from the study of Tobi Inhalation Powder vs nebulised Tobi, which the FDA felt was outweighed by the prospect of better compliance because twice-daily TIP is less time-consuming that twice-daily nebulised Tobi.

      Number of subjects with treatment-emergent adverse events by seriousness -

      1. Serious

      Arikace: 26 out of 148

      Tobi: 29 out of 146

      2. Not serious

      Arikace: 125 out of 148

      Tobi: 113 out of 146

      3. Life Threatening or Disabling

      Arikace: 0 out of 148

      Tobi: 1 out of 146

12.15-0.31(-2.49%)Apr 29 4:00 PMEDT